This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
by Zacks Equity Research
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
5 Winning Stocks With Superb Efficiency Level
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina
by Zacks Equity Research
Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina
Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View
by Zacks Equity Research
Perrigo (PRGO) misses earnings estimates but exceeds revenue expectations in Q1. The company reiterates its revenue and adjusted earnings outlook for 2018.
5 Top Stocks Showing Promise of an Earnings Beat
by Zacks Equity Research
Bet on five stocks that are likely to outdo earnings estimates.
Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.
Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals
by Zacks Equity Research
Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals
4 Top Efficient Stocks to Buy for Stellar Returns
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with its price performance.
Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.
Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced positive results from the phase III trial, CheckMate -078 trial on immuno-oncology drug Opdivo among a predominantly Chinese population.
Can Solid Overall Growth Drive Illumina's (ILMN) Q1 Earnings?
by Zacks Equity Research
Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other segments in Q1.
Illumina Banks on Product Launches & Strategic Partnerships
by Zacks Equity Research
Illumina (ILMN) successfully broadens base by enriching its portfolio of sequencing products and building strategic partnerships with therapeutic and diagnostic service providers.
Illumina Banks on Strategic Partnerships, Competition Rife
by Zacks Equity Research
Illumina's (ILMN) recently-signed partnership to distribute Thermo Fisher's Ion AmpliSeq technology is encouraging.
Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance
by Zacks Equity Research
Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.
Why Illumina (ILMN) Might Surprise This Earnings Season
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Illumina's (ILMN) Q4 Earnings to Show Growth in All Lines
by Zacks Equity Research
Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other revenue segments in Q4.
Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq
by Zacks Equity Research
Illumina (ILMN) consistently tries to enhance NGS platform.
Pacific Biosciences Hurt by Competition in Niche Markets
by Zacks Equity Research
Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.
Illumina (ILMN) Looks Good: Stock Adds 6.9% in Session
by Zacks Equity Research
Illumina (ILMN) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.
Product Innovation Drives Illumina, Downbeat Margins a Woe
by Zacks Equity Research
Illumina (ILMN) harbors hopes about recent launches like NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System. A low margin scenario due to the NovaSeq launch is a concern.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) banks on product launches and international market prospects.
Top Analyst Reports for Home Depot, Boeing & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Boeing (BA) and Merck (MRK).
Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx
by Zacks Equity Research
Illumina (ILMN) expands NGS platform. The company has a solid diagnostic NGS portfolio, which includes NextSeq 550Dx and MiSeqDx.
Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong
by Zacks Equity Research
Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q3
by Zacks Equity Research
Omnicell (OMCL) witnessed year-over-year growth in revenues on the back of its Medication Adherence segment in Q3.